Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the Morris County site last year, filings with the New Jersey Department of Labor ...

The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...

By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas Narasimhan said on Monday.